Search results
Results from the WOW.Com Content Network
Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its potentially groundbreaking treatment since its July IPO, fueling bold analyst predictions. Based on the company's share price of ...
This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...
In December 2023, Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. [ 31 ] [ 32 ] Subsidiaries and former subsidiaries
This figure went up sharply in 2020 as biotech companies managed to raise nearly $$7 billion during the first 7 months of the year through IPOs. Biotech companies usually raise even more capital ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2] In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. [3]
For premium support please call: 800-290-4726 more ways to reach us
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City.It also has operations in Warrendale, PA and Brighton, MA.The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly.